Allergy最新文献

{"title":"Fish Allergenicity Ladder and Parvalbumin Epitopes for Predicting Clinical Cross-Reactivity and Reintroduction in Chinese Population.","authors":"Christine Y Y Wai,Nicki Y H Leung,Agnes S Y Leung,Man Fung Tang,Åsa Marknell DeWitt,Jaime S Rosa Duque,Gilbert T Chua,Yat Sun Yau,Wai Hung Chan,Po Ki Ho,Mike Y W Kwan,Qun Ui Lee,Joshua S C Wong,Ivan C S Lam,James W C H Cheng,David C K Luk,Zhongyi Liu,Noelle Anne Ngai,Oi Man Chan,Patrick S C Leung,Gary W K Wong,Ting Fan Leung","doi":"10.1111/all.16562","DOIUrl":"https://doi.org/10.1111/all.16562","url":null,"abstract":"BACKGROUNDIgE-mediated fish allergy has long been considered an umbrella term due to the high cross-reactivity of parvalbumin, the major fish allergen. Yet, clinical tolerance to certain fish highlights allergenicity differences. In this study, we sought to construct a fish allergenicity ladder and identify fish parvalbumin epitopes to improve the diagnosis of fish allergy.METHODSReported clinical history and the serum-specific IgE (sIgE) responses of 200 Chinese subjects with suspected fish allergy were collected and analyzed, while the relative parvalbumin content in different fish was measured for the construction of a fish allergenicity ladder. Double-blind placebo-controlled food challenge (DBPCFC) and open challenge against salmon, grass carp, and grouper were performed in 58 selected patients for validation of the ladder. Epitope mapping was performed by peptide array against parvalbumins of salmon (both β-1 and β-2), cod, grouper, and grass carp with sera from fish allergic (n = 11), partial fish tolerant (n = 12), and complete fish tolerant (n = 5) patients diagnosed based on oral food challenge outcome.RESULTSThe distribution pattern of reported history of fish allergy and tolerance, sIgE and molecular data, as well as their strong positive correlation led to the construction of a 3-step fish allergenicity ladder comprising: step 1 of the least allergenic fishes (tuna, halibut, salmon and cod), steps 2 of moderately allergenic fishes (herring and grouper) to step 3 of highly allergenic fishes (catfish, grass carp and tilapia). Epitope mapping revealed one epitope from grouper parvalbumin (AA64-78) for diagnosing general fish allergy and one epitopic region from salmon parvalbumin (AA19-33) as a biomarker of specific fish tolerance. Only epitope-specific IgE differentiated these patients but not sIgE to fish extract or parvalbumin.CONCLUSIONThe fish ladder and epitopes discovery can precisely differentiate fish-allergic and tolerant subjects and guide fish reintroduction by stepping up the ladder, which innovates fish allergy care in the next millennium.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"7 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential DNA Methylation in Peripheral Blood Mononuclear Cells Reflects Asthma Control Status in Adults","authors":"Jin An, Jaehyun Park, Ah. Ra Do, Sujin Seo, Eunsoon Shin, Jong Eun Lee, You Sook Cho, Sungho Won, Tae-Bum Kim","doi":"10.1111/all.16566","DOIUrl":"10.1111/all.16566","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"80 6","pages":"1773-1775"},"PeriodicalIF":12.6,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asthma Alleviation by Ginsenoside Rb1 via Promotion of Treg Proliferation and Inflammatory T Cell Inhibition","authors":"Susanna Choi,&nbsp;Seung-Ah Yoo,&nbsp;Kon-Young Ji,&nbsp;Dong Ho Jung,&nbsp;Saseong Lee,&nbsp;Kang-Gu Lee,&nbsp;Ki-Myo Kim,&nbsp;Joo Young Lee,&nbsp;Myung-A Jung,&nbsp;Bo-Jeong Pyun,&nbsp;Jung Hur,&nbsp;Joon Young Choi,&nbsp;Chin Kook Rhee,&nbsp;Wan-Uk Kim,&nbsp;Taesoo Kim","doi":"10.1111/all.16551","DOIUrl":"10.1111/all.16551","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Regulatory T cells (Tregs) are living drugs with feasibility, tolerability, and therapeutic benefits. Although Tregs are linked to asthma prognosis through inflammation regulation, no therapeutic agents specifically designed to manage asthma by upregulating Tregs have been developed to date.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We screened a library of 250 natural products using a cytometric bead array. Among the selected candidates, gRb1 was identified for further investigation. The effects of gRb1 on Treg and Th17 populations were evaluated in mouse asthma models and human PBMCs from both healthy donors and asthma patients using flow cytometry and cytokine analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In inflammatory conditions, ginsenoside Rb1 (gRb1, a major ginseng component) increased IL-10- and TGF-β-expressing Treg populations and decreased the Th17 population; activated phospho-STAT5 and NFAT1 in Tregs; inhibited NFAT1 activation in conventional T cells (Tconvs); increased Treg proliferation and Tconv–Treg differentiation, inhibiting Tconv proliferation; and reduced inflammatory cytokine secretion by Tconvs. In asthma model mice, suppression of asthma symptoms by gRb1 was associated with elevated Treg and lower Th17, Th1, and Th2 counts. gRb1 treatment of stimulated PBMCs from patients with asthma and healthy donors increased IL-10- and TGF-β-expressing Treg populations and decreased IL-17A-, IL-22-, IFN-γ-, and TNF-α-expressing T-cell populations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>gRb1 alleviate asthma by shifting the Treg–inflammatory T cell balance. These findings suggest a strategy for enhancing Treg activity through treatment with gRb1. This may provide a novel therapeutic approach for asthma and related disorders.</p>\u0000 </section>\u0000 </div>","PeriodicalId":122,"journal":{"name":"Allergy","volume":"80 6","pages":"1647-1668"},"PeriodicalIF":12.6,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.16551","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient‐Reported Outcomes in the Phase III OASIS‐HAE Study of Donidalorsen for Hereditary Angioedema","authors":"Marc A. Riedl, Aaron Yarlas, Laura Bordone, Sabrina Treadwell, Sophie Wang, Kenneth B. Newman, Danny M. Cohn","doi":"10.1111/all.16563","DOIUrl":"https://doi.org/10.1111/all.16563","url":null,"abstract":"BackgroundHereditary angioedema (HAE) is a rare disease characterized by unpredictable, frequently severe swelling that negatively impacts patients' quality of life (QoL). In the phase III OASIS‐HAE study (NCT05139810), donidalorsen reduced HAE attack rate, increased disease control, and improved QoL. Here, we report further analysis of donidalorsen's impact on QoL and other patient‐reported outcomes (PROs).MethodsThis double‐blind, placebo‐controlled study randomized patients with HAE to donidalorsen 80 mg or placebo once every 4 (Q4W) or 8 weeks (Q8W) over 24 weeks. PROs included Angioedema (AE)‐QoL Questionnaire, Angioedema Control Test (AECT), Patient Global Impression of Severity (PGIS), and Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions (WPAI+CIQ).ResultsNinety patients received donidalorsen Q4W (<jats:italic>n</jats:italic> = 45), donidalorsen Q8W (<jats:italic>n</jats:italic> = 23), or placebo (<jats:italic>n</jats:italic> = 22). A larger percentage of the donidalorsen Q4W group (88%) achieved clinically meaningful improvement (≥ 6‐point reduction) in AE‐QoL total score vs. placebo (45%). Both donidalorsen groups reported larger least‐squares mean (LSM) changes from baseline to week 24 vs. placebo in AE‐QoL functioning (difference: Q4W, −24.5; Q8W, −16.1), fears/shame (Q4W, −23.9; Q8W, −20.1), and nutrition (Q4W, −15.7; Q8W, −10.7) domains. Donidalorsen improved AECT scores vs. placebo (difference: Q4W, 6.0; Q8W, 4.1). A greater proportion of the donidalorsen Q4W group reported decreased disease severity vs. the placebo group (PGIS; 82% vs. 44%). Donidalorsen Q4W showed benefits vs. placebo in the presenteeism, overall work/school impairment, and activity impairment domains of the WPAI+CIQ.ConclusionsDonidalorsen significantly improved QoL and other PROs vs. placebo in patients with HAE.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"10 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating Mast Cell Progenitors Are Depleted by Benralizumab in Severe Asthma","authors":"Michael Fricker,&nbsp;John Harrington,&nbsp;Sarah A. Hiles,&nbsp;Peter G. Gibson","doi":"10.1111/all.16553","DOIUrl":"10.1111/all.16553","url":null,"abstract":"&lt;p&gt;Inappropriate mast cell (MC) accumulation and activation in the airways promote symptoms and are associated with eosinophilia/T2 inflammation in severe asthma (SA) [&lt;span&gt;1&lt;/span&gt;]. MC-targeted therapeutics are in use (anti-IgE omalizumab) or in development. The origin of increased airway MC numbers in SA is poorly understood. Circulating MC progenitors (MCPs) seed increased airway MCs in mouse models of airway inflammation and infection; however, the clinical associations and therapeutic targeting of MCPs in SA are unstudied [&lt;span&gt;2, 3&lt;/span&gt;]. MCPs are IgE-responsive; thus, they may be impacted by omalizumab treatment, but the effect of T2 cytokine biologics on MCP number and phenotype in SA is unknown.&lt;/p&gt;&lt;p&gt;We performed an observational study, titled “Effect of mepolizumab on alternative functions of eosinophils in severe eosinophilic asthma (ALTEOS)”, to determine the impact of mepolizumab and benralizumab treatment of SA on MCPs. Study design, endpoints and participant characteristics of ALTEOS are published [&lt;span&gt;4&lt;/span&gt;]. MCPs were measured in PBMCs using flow cytometry (Table S1 and Figure S1: CD45&lt;sup&gt;lo&lt;/sup&gt;, CD4&lt;sup&gt;−&lt;/sup&gt;, CD8&lt;sup&gt;−&lt;/sup&gt;, CD19&lt;sup&gt;−&lt;/sup&gt;, CD14&lt;sup&gt;−&lt;/sup&gt;, CD34&lt;sup&gt;+&lt;/sup&gt;, CD117&lt;sup&gt;+&lt;/sup&gt;, FcεR1A&lt;sup&gt;+&lt;/sup&gt; progenitors [&lt;span&gt;2, 3&lt;/span&gt;]) in a cross-sectional study of 80 SA participants (eosinophilic [EA] &lt;i&gt;n&lt;/i&gt; = 32, non-eosinophilic [NEA] &lt;i&gt;n&lt;/i&gt; = 23, mepolizumab-treated &lt;i&gt;n&lt;/i&gt; = 25). EA was defined as any peripheral blood eosinophil (PBE) count ≥ 300/μL at baseline visit or in the 12 months prior, or ≥ 150/μL while receiving maintenance OCS treatment. Proportion and number of MCPs did not differ between NEA, EA and mepolizumab-treated SA (Figures 1A, S2A). Two of 23 NEA, 9 of 32 EA and 3 of 25 mepolizumab-treated SA were treated with maintenance OCS [&lt;span&gt;4&lt;/span&gt;]. MCP did not differ between OCS and non-OCS treated participants (Figure S2B). Of the 32 EA cross-sectional (v1) participants, 20 subsequently commenced mepolizumab and 10 benralizumab, and MCPs were measured at v2 (8–24 weeks) and v3 (&gt; 24 weeks) post-treatment. MCPs were unaltered at v2 and v3 compared to baseline in mepolizumab-treated patients (Figures 1B, S2C,D). In contrast, MCPs were significantly decreased at follow-up in benralizumab-treated patients (Figures 1B, S2E–G). A greater proportion of MCPs expressed detectable IL5 receptor subunit alpha/CD125 (the target of benralizumab) compared to CD34&lt;sup&gt;+&lt;/sup&gt;, CD117&lt;sup&gt;+&lt;/sup&gt;, FcεR1A&lt;sup&gt;−&lt;/sup&gt; progenitors (termed non-MCP), while IL4R/CD124 (the target of dupilumab) expression was undetectable (Figure 1C,D). IL5R&lt;sup&gt;+&lt;/sup&gt; MCPs expressed increased surface CD117 and FcεR1A compared to IL5R&lt;sup&gt;−&lt;/sup&gt; MCPs, consistent with acquisition of IL5R expression as MCPs progress toward MC commitment (Figure 1E,F) [&lt;span&gt;5&lt;/span&gt;]. Neither IL5R&lt;sup&gt;+&lt;/sup&gt; nor IL5R&lt;sup&gt;−&lt;/sup&gt; proportion, number or viability were altered by mepolizumab, suggesting MCPs are not IL5-dependent f","PeriodicalId":122,"journal":{"name":"Allergy","volume":"80 6","pages":"1797-1800"},"PeriodicalIF":12.6,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.16553","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143853077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early-Life Quarantine Increases the Development of Infant Atopic Dermatitis: A Birth Cohort Study in China","authors":"Yi Hu,&nbsp;Jiuru Zhao,&nbsp;Qianwen Shen,&nbsp;Dongjian Yang,&nbsp;Wei Li,&nbsp;Ze Chen,&nbsp;Meng Ni,&nbsp;Baihe Li,&nbsp;Zhenying Lin,&nbsp;Chunyu Cheng,&nbsp;Dongting Yao,&nbsp;Qianqian Zhang,&nbsp;Xiaorui Liu,&nbsp;Hong Li,&nbsp;Xiaoyi Huang,&nbsp;Zheng Tang,&nbsp;Zhiwei Liu","doi":"10.1111/all.16561","DOIUrl":"10.1111/all.16561","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"80 5","pages":"1526-1529"},"PeriodicalIF":12.6,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelin-1 Participates in the Pathogenesis of Prurigo Nodularis by Promoting NGF Expression via Endothelial Receptor B in Epidermal Keratinocytes and Dorsal Root Ganglion Cells","authors":"Lai-San Wong,&nbsp;Jenq-Lin Yang,&nbsp;Yu-Ta Yen,&nbsp;Chih-Hung Lee,&nbsp;Jen-Hau Yang","doi":"10.1111/all.16564","DOIUrl":"10.1111/all.16564","url":null,"abstract":"&lt;p&gt;Prurigo nodularis (PN) is a debilitating chronic skin disorder characterized by intractable itch and nodular lesions [&lt;span&gt;1&lt;/span&gt;]. While its exact etiology remains unclear, emerging evidence suggests a complex interplay between neuronal sensitization and cutaneous changes [&lt;span&gt;2&lt;/span&gt;]. Recent studies indicate increased epidermal branching and heightened expression of neuroplasticity-related genes regulating sensory neuron growth in PN [&lt;span&gt;3&lt;/span&gt;]. Notably, nerve growth factor (NGF), a neurotrophic factor essential for nociceptive signaling [&lt;span&gt;4&lt;/span&gt;], is highly expressed in PN compared to atopic dermatitis (AD) and brachioradial pruritus. Its elevated expression correlates with increased epidermal nerve fiber branching [&lt;span&gt;3&lt;/span&gt;]. This NGF-mediated neuroplasticity may contribute to neuronal alterations in PN.&lt;/p&gt;&lt;p&gt;In our previous study, we identified significantly elevated endothelin-1 (EDN1) expression in PN lesional skin and serum, suggesting its role in local and systemic modulation [&lt;span&gt;5&lt;/span&gt;]. Recent single-cell analysis further revealed increased EDN1 expression in PN compared to AD and healthy controls, underscoring its disease-specific significance [&lt;span&gt;6&lt;/span&gt;]. While EDN1 is recognized as a histamine-independent pruritogen [&lt;span&gt;7&lt;/span&gt;], its role in neural sensitization remains unclear. In particular, its direct impact on dorsal root ganglion (DRG) neurons has not been explored. Here, we investigate the interaction between EDN1 and NGF in keratinocytes and DRG neurons, contributing to neuronal sensitization in PN.&lt;/p&gt;&lt;p&gt;To elucidate the role of NGF, we assessed NGF and brain-derived neurotrophic factor (BDNF) expression in PN lesional skin, as BDNF, another neurotrophic factor involved in neuronal growth and sensitization, was assessed for comparison. Immunofluorescence revealed significantly higher epidermal NGF expression in PN (5.25 ± 2.49) than in healthy controls (1.09 ± 0.93, &lt;i&gt;p&lt;/i&gt; &lt; 0.01) (Figure 1a), whereas BDNF expression remained comparable (Figure S1a). Serum NGF levels did not differ significantly between patients with PN (113.28 ± 143.17 pg/mL) and controls (490.22 ± 703.97 pg/mL), indicating a localized NGF effect in PN pathogenesis (Figure 1a).&lt;/p&gt;&lt;p&gt;Next, we examined how EDN1 regulates NGF expression in the epidermis. Immunofluorescence demonstrated increased NGF expression following EDN1 (100 nM) stimulation in keratinocytes (Figure S1b). Western blot analysis revealed a peak in NGF protein levels at 18 h poststimulation (Figure S1c). siRNA knockdown of EDNRA and EDNRB in HaCaT cells showed that EDN1-induced NGF upregulation was significantly attenuated in EDNRB-deficient cells but remained unaffected by EDNRA knockdown (Figure 1b). These findings indicate that EDNRB, rather than EDNRA, is the key mediator of EDN1-induced NGF expression in keratinocytes.&lt;/p&gt;&lt;p&gt;Given the key role of neuronal pathways in PN, we investigated EDN1's impact on NGF expression in DRG neurons. EDN1","PeriodicalId":122,"journal":{"name":"Allergy","volume":"80 5","pages":"1530-1533"},"PeriodicalIF":12.6,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.16564","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial.","authors":"Caroline Holzmann,Johannes Karg,Matthias Reiger,Rajiv Kharbal,Paola Romano,Sabrina Scheiwein,Claudia Khalfi,Anna Muzalyova,Jens O Brunner,Gertrud Hammel,Athanasios Damialis,Claudia Traidl-Hoffmann,María P Plaza,Stefanie Gilles","doi":"10.1111/all.16558","DOIUrl":"https://doi.org/10.1111/all.16558","url":null,"abstract":"BACKGROUNDSymptom monitoring can improve adherence to daily medication. However, controlled clinical trials on multi-modular allergy apps and their various functions have been difficult to implement. The objective of this study was to assess the clinical benefit of an allergy app with varying numbers of functions in reducing symptoms and improving quality of (QoL) life in grass pollen allergic individuals. The secondary objective was to develop a symptom forecast based on patient-derived and environmental data.METHODSWe performed a stratified, controlled intervention study (May-August 2023) with grass pollen allergic participants (N = 167) in Augsburg, Germany. Participants were divided into three groups, each receiving the same allergy app, but with increasing numbers of functions.PRIMARY ENDPOINTrhinitis-related QoL; Secondary endpoints: symptom scores, relevant behavior, self-reported usefulness of the app, symptom forecast.RESULTSRhinitis-related QoL was increased after the intervention, with no statistical inter-group differences. However, participants with access to the full app version, including a pollen forecast, took more medication and reported lower symptoms and social activity impairment than participants with access to a reduced-function app. Using an XGBoost multiclass classification model, we achieved promising results for predicting nasal (accuracy: 0.79; F1-score: 0.78) and ocular (accuracy: 0.82; F1-score: 0.76) symptom levels and derived feature importance using SHAP as a guidance for future approaches.CONCLUSIONOur allergy app with its high-performance pollen forecast, symptom diary, and general allergy-related information provides a clinical benefit for allergy sufferers. Reliable symptom forecasts may be created given high-quality and high-resolution data.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"28 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Otitis Media With Effusion (OME) and Eustachian Tube Dysfunction: The Role of Allergy and Immunity-An EAACI Position Paper.","authors":"L Klimek,H A Brough,S Arasi,S Toppila-Salmi,C Bergmann,M Jutel,J Bousquet,V Hox,P Gevaert,P V Tomazic,C Rondón Segovia,C Cingi,M Cuevas,M Gröger,P Huber,S Reitsma,M Rudenko,J Maza-Solano,S Gane,A Karavelia,L van Gerven,M Schiappoli,B Bozkurt,S Becker,A Chaker,B Wollenberg,R Mösges,T Huppertz,J Hagemann,O Palomares,F Bärhold,O Pfaar,S Del Giacco,P Bonadonna,A Moreira,I Agache,C A Akdis,W Fokkens,J Walusiak-Skorupa,L de Las Vecillas,M Alvaro Lozano,M Giovannini,E Untersmayr,W Feleszko,A Cianferoni,U M Sahiner,I Eguiluz-Gracia,M Shamji,M J Torres Jaén","doi":"10.1111/all.16554","DOIUrl":"https://doi.org/10.1111/all.16554","url":null,"abstract":"IgE-mediated allergies play a significant role in respiratory diseases. Given the similar mucosal epithelium of the upper and lower respiratory tracts and their shared (patho)physiological immune responses, the \"unified airways\" concept views these tracts as a single system. Recently, this model has been extended to include the middle ear, with studies confirming that the Eustachian tube and middle ear are both anatomically and functionally part of the upper airways. However, the relationship between allergies and middle ear disorders remains controversial, with conflicting findings regarding pathogenesis and treatment. The increasing prevalence of allergies highlights the importance of further research. In Germany, the current sensitization rate to aeroallergens is 33.6%, with similar trends across Europe, where rates commonly range up to 30%. This widespread increase underscores the urgent need for a deeper understanding of the correlation between allergies and middle ear disorders across diverse European populations. Ineffective pharmacotherapy or possibly harmful medication for acute and chronic OME, such as systemic steroids, is most likely used globally in an uninformed way, due to a lack of evidence on the connection between allergic inflammation and eustachian tube dysfunction. Further research is essential to clarify the mechanisms linking IgE-mediated allergies to middle ear pathologies and to develop effective treatment strategies. Addressing these knowledge gaps is critical for improving patient outcomes and managing the rising burden of allergic diseases.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"7 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence to \"Omalizumab Reduces Anaphylactic Reactions and Allows Food Introduction in Food-Allergic in Children With Severe Asthma: An Observational Study\".","authors":"Angela Klain,Cristiana Indolfi,Carolina Grella,Simone Colosimo,Alessandra Perrotta,Michele Miraglia Del Giudice","doi":"10.1111/all.16560","DOIUrl":"https://doi.org/10.1111/all.16560","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"4590 5 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}